Recent Updates — THAR

Canton Strategic Holdings, Inc. completed the sale of its wholly owned subsidiary, Gravitas Life Sciences, LLC, to Gravitas Collective Corp. on July 17, 2026. The consideration included an unsecured promissory note for $3,500,000 with a 15% annual interest rate compounding semi-annually and a maturity date of July 17, 2029, plus potential development milestone payments. The company retained certain assets related to bispecific antibodies development through its subsidiary Tharimmune SPV1. Canton Strategic Holdings operates as a strategic investor and operator leveraging the Canton Network to digitize traditional financial markets using blockchain technology.